Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 3, 2022 4:01 PM EDTQ2 2022 total revenues were $64.4 millionTotal revenues in the first six months of 2022 were $124.6 millionVanda provides update on pipeline advancements and upcoming milestones
WASHINGTON, Aug. 3, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022.
"During the second quarter we made significant progress towards commercializing our products and improving access to HETLIOZ® for patients with Non-24," said Mihael H.... More
